Abstract
The pathophysiologic relevance of autoantibodies against cardiac proteins in the induction or maintenance of idiopathic dilated cardiomyopathy is still unclear. It has been shown that induction of antibodies against cardiac β1-adrenergic–receptor structures in rabbits leads to significant cardiac dilatation.1,2 Examinations of cardiac myocytes from neonatal rats have shown that this antibody type isolated from patients with idiopathic dilated cardiomyopathy acts like a β-adrenergic agonist.3 Removal of class G immunoglobulins from plasma has been shown to improve cardiac performance within one year after immunoadsorption in patients with idiopathic dilated cardiomyopathy.4 Since immunoadsorption removes a whole class of immunoglobulins, all autoantibodies of that particular class were eliminated. We report the effect on cardiac performance of selective elimination of autoantibodies against the β1-adrenergic receptor after one year in eight patients. The prevalence of these autoantibodies in patients with idiopathic dilated cardiomyopathy is about 80 percent.4